Please note that LIDDS will disclose information in Press releases only in English going forward. Vänligen notera att LIDDS fortsättningsvis kommer att offentliggöra pressmeddelanden endast på engelska. Erik Penser temadag med bolag i cancerforskningens frontlinje, Stockholm, October 6, 2020, Monica Wallter, CEO LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months. Visitingadress: Virdings allé 32b, Uppsala LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.comPress releases
LIDDS’ NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect LIDDS announces outcome of subscription of shares in the incentive programs 2017/2020 LIDDS Announces Data on Liproca Depot from Open Label Extension Study LIDDS Delårsrapport januari – juni 2020Events
Company Analysis
Photo Library
Lidds
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.comFinancial Calendar
Subscribe for news
Press releases
LIDDS’ NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect LIDDS announces outcome of subscription of shares in the incentive programs 2017/2020 LIDDS Announces Data on Liproca Depot from Open Label Extension Study LIDDS Delårsrapport januari – juni 2020
press
LIDDS företrädesemission kraftigt övertecknad
events
analysis
